Search

1 to 10 of 560
Sort by

Library Entry
PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article suggesting that mitochondria are the main targets of PD-1 inhibitory activity. PD-1 reprograms CD8 + T cell metabolism for efficient use of fatty acid oxidation; this mitochondrial phenotype might explain the...


Library Entry
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report discussing the role of B cells in the anti-tumor activity of PD-1 inhibitors and their activity in mouse models receiving B cell depleting drugs or with immunoglobulin deficiencies. Authors: William Damsky , Lucia...


Library Entry
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article demonstrating that high numbers of peripheral CD8 T cells expressing differentiation markers and lacking co-stimulatory receptors at baseline are associated with response to nivolumab in NSCLC patients. Authors: ...


Library Entry
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article providing evidence for co-expression of multiple immune checkpoint genes including, PD-1 , PD-L1, IDO1, TIGIT, TIM-3, TGFB1, LAG3, and others, that potentially contribute to compensatory immune evasion in...


Library Entry
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report discussing immuno-PET studies of PD-L1 in a preclinical tumorgraft model of clear cell RCC (ccRCC) from a patient who had a favorable response to anti-PD-1 therapy. Authors: Joseph Vento , Aditi Mulgaonkar , ...


Library Entry
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report describing a patient with myasthenia gravis treated with pembrolizumab demonstrating successful outcomes. Authors: Anne Zaremba , Eleftheria Chorti , Finja Jockenhöfer , Saskia Bolz , Selma Sirin , Martin Glas ,...


Library Entry
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article supporting the development of D2C7-IT and immune checkpoint blockade combinations for patients with malignant glioma. Authors: Vidyalakshmi Chandramohan, Xuhui Bao , Xin Yu , Scott Parker , Charlotte...


Library Entry
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which a listeria vaccine-based immunotherapy was shown to be able to induce a tumor antigen-specific T cell response within the tumor microenvironment of a “cold” tumor such as PDAC and sensitize the tumor to...


Library Entry
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article concluding that ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations. Authors: Douglas B....


Library Entry
The promise of Immuno-oncology: implications for defining the value of cancer treatment

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a position article and guidelines. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of...